Isatuximab - Wikipedia
Isatuximab is a monoclonal antibody (mAb) designed for the treatment of cancer. It was developed by ImmunoGen and Sanofi-Aventis with the development name SAR-650984 . It was given orphan drug status for multiple myeloma by the FDA in December 2016. ... Read Article
Jakafi Prescribing Information
Jakafi is a kinase inhibitor indicated for treatment of patients with: • intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis. ... Return Document
H Antagonist (ranitidine 50 Mg Or Equivalent H Antagonist) (2 ...
JEVTANA is a microtubule inhibitor indicated in combination with prednisone for treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing treatment regimen. ... Retrieve Document
HIGHLIGHTS OF PRESCRIBING INFORMATION ...
3 • The recommended initial doseis 400mg/m2administered as a 120-minute intravenous infusion. • The recommended subsequent dosage (all other infusions) is 250mg/m2weekly as a60-minuteinfusionuntil disease progression or unacceptable toxicity. ... Doc Viewer
Reference ID: 3161927 - Food And Drug Administration
KYPROLIS™ (carfilzomib) for Injection, for intravenous use Initial U.S. Approval: 2012 . KYPROLIS is a proteasome inhibitor indicated for the treatment of patients with Reference ID: 3161927 . FULL PRESCRIBING INFORMATION 1 . INDICATIONS AND USAGE . ... Return Doc
HIGHLIGHTSOF PRESCRIBING INFORMATION KYPROLIS Safely And ...
HIGHLIGHTSOF PRESCRIBING INFORMATION These highlights do not include all the information needed to use KYPROLIS safely and effectively. See full prescribing information for KYPROLIS. KYPROLIS® (carfilzomib) for injection, for intravenous use Initial U.S. Approval: 2012-----RECENT MAJOR CHANGES----- ... Access Content
HIGHLIGHTS OF PRESCRIBING INFORMATION Patients At Risk Of ...
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TARCEVA® safely and effectively. See full prescribing information for ... Fetch Full Source
CONTRAINDICATIONS------------------------------
2.6 Preparation of VIDAZA VIDAZA is a cytotoxic drug. Follow applicable special handling and disposal procedures. 1 The VIDAZA vial is single-dose and does not contain any preservatives. Discard unused portions of each vial properly [see How Supplied/Storage and Handling (16)]. Do not save any unused portions for later administration. ... Read More
HIGHLIGHTS OF PRESCRIBING INFORMATION With A Fluoropyrimidine ...
3 FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE 1.1 Melanoma KEYTRUDA®(pembrolizumab) is indicated for the treatment of patients with unresectable or metastatic melanoma [see Clinical Studies (14.1)]. 1.2 Non-Small Cell Lung Cancer ... Return Document
Kyprolis® (carfilzomib) - Magellan Provider
1. Kyprolis [package insert]. Thousand Oaks, CA; Onyx Pharmaceuticals Inc; September 2018. Accessed October 2018. 2. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Carfilzomib. National Comprehensive Cancer Network, 2018. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL ... Read Document
Kyprolis (carfilzomib) - Caremark
Kyprolis 2 Current oncology notes, clinical notes that include the history of previous treatments, and any pertinent pathology reports and/or imaging studies. ... Get Content Here
Page 1 Of 24 - Ninlarohcp.com
Page 1 of 24 HIGHLIGHTS OF PRESCRIBING INFORMATION • These highlights do not include all the information needed to use NINLARO safely and effectively. ... Get Content Here
MODA MRxM Kyprolis 05 18
1. Kyprolis [package insert]. San Francisco, CA; Onyx Pharmaceuticals Inc; January 2018. Accessed March 2018. 2. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Carfilzomib. National Comprehensive Cancer Network, 2018. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL ... Fetch This Document
HIGHLIGHTS OF PRESCRIBING INFORMATION Renal Toxicity May Be ...
Upon treatment initiation, the recommended Zometa doses for patients with reduced renal function (mild and moderate renal impairment) are listed in Table 1. ... Retrieve Content
US-22058 HIGHLIGHTS PRESCRIBING INFORMATION ...
Taken with food. Please refer to the Full Prescribing Information for palbociclib. When FASLODEX is used in combination with abemaciclib, the recommended dose . of abemaciclib is 150 mg orally, twice daily. Abemaciclib may be taken with or without food. Please refer to the Full Prescribing Information for abemaciclib. ... Retrieve Doc
HIGHLIGHTS OF PRESCRIBING INFORMATION These Highlights Do Not ...
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use EMPLICITI safely and effectively. See full prescribing information for EMPLICITI. ... Return Document
Reference ID: 3876199 - Food And Drug Administration
2 2 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use KYPROLIS safely and effectively. ... Retrieve Content
Effective Date: 05/03/2018 - Bcbsm.com
Dimopoulos MA, Moreau P, Palumbo A et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomized, phase 3 ... Visit Document
HIGHLIGHTS OF PRESCRIBING INFORMATION The Dose For RA In ...
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use RITUXAN safely and effectively. See full prescribing information for ... Fetch Content
Daratumumab (DARA) In Combination With carfilzomib And ...
Combining DARA With Carfilzomib • Carfilzomib (K) is a PI approved for the treatment of RRMM patients. 1 – In combination with dexamethasone, once-weekly dosing with K 20/70 mg/m ... Read Here
No comments:
Post a Comment